About Bluejay Therapeutics
Bluejay Therapeutics is a private company based in San Mateo, California, incorporated in 2019 in Delaware. It has reported $221,739,912 raised in three offerings on Form D since June 2021. Its chief executive is Keting Chu.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 1, 2024 | May 10, 2024 | $181,999,946fully sold | 19 | $9.5M | EquityRule 506(b) | Form D ↗ |
| Aug 9, 2022 | Aug 16, 2022 | $20,499,976of $41.1M target | 9 | $2.2M | EquityRule 506(b) | Form D ↗ |
| Jun 10, 2021 | Jun 21, 2021 | $19,239,990of $24.2M target | 6 | $3.2M | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $221,739,912 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Bluejay Therapeutics's Form D filed May 10, 2024.
DE
Dan Estes
Director
PK
Pascal Krotee
Director
JL
Jianqing Li
Director
KC
Keting Chu
Chief Executive Officer and director
AL
Alon Lazarus
Director
DY
Dajun Yang
Director
Earlier filings also listed William Rutter (director, last listed Aug 2022), Wen Chen (director, last listed Aug 2022), Ting Jia (director, last listed Aug 2022) and Nancy Hong (director, last listed Aug 2022).